




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C07D 211/52, A61K 31/445, C07D 405/06, 409/06, 493/04 // (C07D 493/04, 317:00, 313:00)</p>	A1	<p>(11) International Publication Number: WO 99/37617 (43) International Publication Date: 29 July 1999 (29.07.99)</p>
<p>(21) International Application Number: PCT/US99/01265 (22) International Filing Date: 21 January 1999 (21.01.99) (30) Priority Data: 09/010,321 21 January 1998 (21.01.98) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 09/010,321 (CIP) Filed on 21 January 1998 (21.01.98) (71) Applicant (for all designated States except US): LEUKOSITE, INC. [US/US]; 215 First Street, Cambridge, MA 02142 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): SCHWENDER, Charles, F. [US/US]; 577 East Hill Road, Glen Gardner, NJ 08826 (US). MACKAY, Charles, R. [AU/US]; 126 Church Street, Watertown, MA 02472 (US). PINTO, Julia, C. [US/US]; 8 Chubb's Brook Lane, Beverly Farms, MA 01915 (US). NEWMAN, Walter [US/US]; 3 Durham Street #3, Boston, MA 02115 (US).</p>	<p>(74) Agents: CARROLL, Alice, O. et al.; Hamilton, Brook, Smith & Reynolds, P.C., Two Militia Drive, Lexington, MA 02421 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>	

(54) Title: CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR



(57) Abstract

Disclosed is a method of treating a subject with a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to the subject a therapeutically effective amount of a compound represented by structural formula (I), and physiologically acceptable salts thereof. Z is a cycloalkyl or non-aromatic heterocyclic ring group fused to one or more carbocyclic aromatic rings and/or heteroaromatic rings, wherein each ring in Z is independently substituted or unsubstituted; Y is a covalent bond, -O- or -CO-; n is an integer from one to about five; X is a covalent bond or -CO-; and M is >NR₂, >CR₁R₂; R₁ is -H, -OH, an aliphatic group, -O- (aliphatic group), -SH or -S- (aliphatic group); R₂ is an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzylic group, a substituted benzylic group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

-1-

CHEMOKINE RECEPTOR ANTAGONISTS
AND METHODS OF USE THEREFOR

RELATED APPLICATIONS

This application is a continuation-in-part of U.S.
5 Serial No. 09/010,321, filed January 21, 1998, which is a
continuation-in-part of U.S. Serial No. 08/891,518, filed
July 11, 1997, which claims priority to U.S. Provisional
Application Serial No. 60/021,716, filed July 12, 1996, the
entire teachings of which are hereby incorporated by
10 reference.

BACKGROUND OF THE INVENTION

Chemoattractant cytokines or chemokines are a family
of proinflammatory mediators that promote recruitment and
15 activation of multiple lineages of leukocytes and
lymphocytes. They can be released by many kinds of tissue
cells after activation. Continuous release of chemokines at
sites of inflammation mediates the ongoing migration of
effector cells in chronic inflammation. The chemokines
20 characterized to date are related in primary structure.
They share four conserved cysteines, which form disulfide
bonds. Based upon this conserved cysteine motif, the family
is divided into two main branches, designated as the C-X-C
chemokines (α -chemokines), and the C-C chemokines
25 (β -chemokines), in which the first two conserved cysteines
are separated by an intervening residue, or adjacent
respectively (Baggiolini, M. and Dahinden, C. A.,
Immunology Today, 15:127-133 (1994)).

The C-X-C chemokines include a number of potent chemoattractants and activators of neutrophils, such as interleukin 8 (IL-8), PF4 and neutrophil-activating peptide-2 (NAP-2). The C-C chemokines include RANTES
5 (Regulated on Activation, Normal T Expressed and Secreted), the macrophage inflammatory proteins 1 α and 1 β (MIP-1 α and MIP-1 β), and human monocyte chemotactic proteins 1-3 (MCP-1, MCP-2, MCP-3), which have been characterized as chemoattractants and activators of monocytes or lymphocytes
10 but do not appear to be chemoattractants for neutrophils. Chemokines, such as RANTES and MIP-1 α , have been implicated in a wide range of human acute and chronic inflammatory diseases including respiratory diseases, such as asthma and allergic disorders.

15 The chemokine receptors are members of a superfamily of G protein-coupled receptors (GPCR) which share structural features that reflect a common mechanism of action of signal transduction (Gerard, C. and Gerard, N.P., *Annu Rev. Immunol.*, 12:775-808 (1994); Gerard, C. and
20 Gerard, N. P., *Curr. Opin. Immunol.*, 6:140-145 (1994)). Conserved features include seven hydrophobic domains spanning the plasma membrane, which are connected by hydrophilic extracellular and intracellular loops. The majority of the primary sequence homology occurs in the
25 hydrophobic transmembrane regions with the hydrophilic regions being more diverse. The first receptor for the C-C chemokines that was cloned and expressed binds the chemokines MIP-1 α and RANTES. Accordingly, this MIP-1 α /RANTES receptor was designated C-C chemokine
30 receptor 1 (also referred to as CCR-1; Neote, K., et al., *Cell*, 72:415-425 (1993); Horuk, R. et al., WO 94/11504, May

26, 1994; Gao, J.-I. et al., *J. Exp. Med.*, 177:1421-1427 (1993)). Three new receptors have been characterized which bind and/or signal in response to RANTES: CCR3 mediates binding and signaling of chemokines including eotaxin, RANTES, and MCP-3 (Ponath et al., *J. Exp. Med.*, 183:2437 (1996)), CCR4 binds chemokines including RANTES, MIP-1 α , and MCP-1 (Power, et al., *J. Biol. Chem.*, 270:19495 (1995)), and CCR5 binds chemokines including MIP-1 α , RANTES, and MIP-1 β (Samson, et al., *Biochem. J.* 35: 3362-3367 (1996)). RANTES is a chemotactic chemokine for a variety of cell types, including monocytes, eosinophils, and a subset of T-cells. The responses of these different cells may not all be mediated by the same receptor, and it is possible that the receptors CCR1, CCR4 and CCR5 will show some selectivity in receptor distribution and function between leukocyte types, as has already been shown for CCR3 (Ponath et al.). In particular, the ability of RANTES to induce the directed migration of monocytes and a memory population of circulating T-cells (Schall, T. et al., *Nature*, 347:669-71 (1990)) suggests this chemokine and its receptor(s) may play a critical role in chronic inflammatory diseases, since these diseases are characterized by destructive infiltrates of T cells and monocytes.

Many existing drugs have been developed as antagonists of the receptors for biogenic amines, for example, as antagonists of the dopamine and histamine receptors. No successful antagonists have yet been developed to the receptors for the larger proteins such as chemokines and C5a. Small molecule antagonists of the interaction between C-C chemokine receptors and their ligands, including RANTES

and MIP-1 α , would provide compounds useful for inhibiting harmful inflammatory processes "triggered" by receptor ligand interaction, as well as valuable tools for the investigation of receptor-ligand interactions.

5 SUMMARY OF THE INVENTION

It has now been found that a number of small organic molecules are antagonists of chemokine receptor function and can inhibit leukocyte activation and/or recruitment. An antagonist of chemokine receptor function is a molecule
10 which can inhibit the binding of one or more chemokines, including C-C chemokines such as RANTES and/or MIP-1 α , to one or more chemokine receptors on leukocytes and/or other cell types. As a consequence, processes and cellular responses mediated by chemokine receptors can be inhibited
15 with these small organic molecules. Based on this discovery, a method of treating a subject with a disease associated with aberrant leukocyte recruitment and/or activation is disclosed. The method comprises administering to the subject a therapeutically effective
20 amount of a compound or small organic molecule which is an antagonist of chemokine receptor function. Compounds or small organic molecules which have been identified as antagonists of chemokine receptor function are discussed in detail hereinbelow, and can be used for the manufacture of
25 a medicament for treating or for preventing a disease associated with aberrant leukocyte recruitment and/or activation. The invention also relates to the disclosed compounds and small organic molecules for use in treating or preventing a disease associated with aberrant leukocyte
30 recruitment and/or activation. The invention also includes

pharmaceutical compositions comprising one or more of the compounds or small organic molecules which have been identified herein as antagonists of chemokine function and a suitable pharmaceutical carrier. The invention further
5 relates to novel compounds which can be used to treat an individual with a disease associated with aberrant leukocyte recruitment and/or activation.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 is a schematic showing the preparation of the
10 compounds represented by Structural Formulas (I) and (II).

Figure 2 is a schematic showing the preparation of the compounds represented by Structural Formula ((I) and II), wherein Z is represented by Structural Formulas (IV) and wherein Ring A in Z is substituted with
15 $-(CH_2)_t-COOH$, $-(CH_2)_t-COOR^{20}$ or $-(CH_2)_t-C(O)-NR^{21}R^{22}$.

Figure 3 is a schematic showing the preparation of the compounds represented by Structural Formula (I) and (II), wherein Z is represented by Structural Formulas (VIII) and (XIII)-(XVI) and wherein V is W_a .

20 Figure 4A - 4F show the structures of a number of exemplary compounds of the present invention.

DETAILED DESCRIPTION OF THE INVENTION


The present invention relates to small molecule compounds which are antagonists of chemokine receptor
25 function. Accordingly, processes or cellular responses mediated by the binding of a chemokine to a receptor can be inhibited (reduced or prevented, in whole or in part), including leukocyte migration, integrin activation, transient increases in the concentration of intracellular

free calcium $[Ca^{++}]$, and/or granule release of proinflammatory mediators.

The invention further relates to a method of treatment, including prophylactic and therapeutic treatments, of a disease associated with aberrant leukocyte recruitment and/or activation or mediated by chemokines or chemokine receptor function, including chronic inflammatory disorders characterized by the presence of RANTES, MIP-1 α , MCP-2, MCP-3 and/or MCP-4 responsive T cells, monocytes and/or eosinophils; including but not limited to diseases such as arthritis (e.g., rheumatoid arthritis); atherosclerosis, arteriosclerosis, ischemia/reperfusion injury, diabetes mellitus (e.g., type 1 diabetes mellitus), psoriasis, multiple sclerosis, inflammatory bowel diseases such as ulcerative colitis and Crohn's disease, rejection of transplanted organs and tissues (i.e., acute allograft rejection, chronic allograft rejection), graft versus host disease, as well as allergies and asthma. Other diseases associated with aberrant leukocyte recruitment and/or activation which can be treated (including prophylactic treatments) with the methods disclosed herein are inflammatory diseases associated with Human Immunodeficiency Virus (HIV) infection, e.g., AIDS associated encephalitis, AIDS related maculopapular skin eruption, AIDS related interstitial pneumonia, AIDS related enteropathy, AIDS related periportal hepatic inflammation and AIDS related glomerulo nephritis. The method comprises administering to the subject in need of treatment an effective amount of a compound (i.e., one or more compounds) which inhibits chemokine receptor function, inhibits the binding of a chemokine to leukocytes and/or

other cell types, and/or which inhibits leukocyte migration to, and/or activation at, sites of inflammation. According to the method, chemokine-mediated chemotaxis and/or activation of pro-inflammatory cells bearing receptors for chemokines can be inhibited. As used herein, "pro-inflammatory cells" includes but is not limited to leukocytes, since chemokine receptors may be expressed on other cell types, such as neurons and epithelial cells.

In one embodiment of the present invention, the antagonist of chemokine receptor function is represented by Structural Formula (I):



(I)

Z is a cycloalkyl or non-aromatic heterocyclic ring fused to one or more carbocyclic aromatic rings and/or heteroaromatic rings.

Y is a covalent bond, -O- or -CO-.

n is an integer from one to about five. n is preferably one, two, or three.

20 X is a covalent bond or -CO-.


M is >NR₂ or >CR₁R₂. Preferably, M is >C(OH)R₂.

R₁ is -H, -OH, an aliphatic group, -O-(aliphatic group), -SH or -S-(aliphatic group). Preferably, R₁ is -H or -OH.

25 R₂ is an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a

benzylic group, a substituted benzylic group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group. Preferably, R_2 is an aromatic or a substituted aromatic group.

- 5 In a preferred embodiment, -X- and -Y- in Structural Formula (I) are each a covalent bond and the antagonist of chemokine receptor function is a compound represented by Structural Formula (II):




10

(II)

Z, n and M are as described above for Structural Formula (I).


- In another preferred embodiment, -X- is a covalent bond, -Y- is -CO- and the antagonist of chemokine receptor
15 function is a compound represented by Structural Formula (III):



(III)

- Preferably, Z is a tricyclic ring system comprising
20 two carbocyclic aromatic groups fused to a seven or eight membered cycloalkyl group or to a non-aromatic heterocyclic

ring. In one example, Z is represented by Structural Formula (IV):



(IV)

5 The phenyl rings in Structural Formula (IV), labeled with an "A" and "B", are referred to herein as "Ring A" and "Ring B", respectively. The central ring, labeled with a "C", is referred to as "Ring C" and can be, for example a
 10 (e.g., a cycloheptane or cyclooctane ring) or a non-aromatic heterocyclic ring. When Ring C is a non-aromatic heterocyclic ring, it can contain one or two heteroatoms such as nitrogen, sulfur or oxygen. When Z is represented by Structural Formula (IV), the tricyclic ring system is
 15 connected to Y in Structural Formula (I) by a single covalent bond between Y and a ring atom in Ring C.

Ring A and/or Ring B can be unsubstituted. Alternatively, Ring A and/or Ring B can have one or more substituents. Suitable substituents are as described
 20 hereinbelow for substituted aromatic groups. In one example, Ring A or Ring B is substituted with $-(CH_2)_t-COOH$, $-(CH_2)_t-COOR^{20}$ or $-(CH_2)_t-C(O)-NR^{21}R^{22}$.


t is an integer from zero to about 3.

R^{21} , R^{21} or R^{22} are independently -H, an aliphatic group
a substituted aliphatic group, an aromatic group, a
substituted aromatic group, -NHC(O)-O-(aliphatic group),
-NHC(O)-O-(aromatic group) or -NHC(O)-O-(non-aromatic
5 heterocyclic group). In addition, R^{21} and R^{22} , taken
together with the nitrogen atom to which they are bonded,
can form a non-aromatic heterocyclic ring.


Ring C optionally contains one or more additional
substituents. When Ring C is a non-aromatic carbocyclic
10 ring, suitable substituents are as described hereinbelow
for substituted aliphatic groups. When Ring C contains one
or more heteroatoms, suitable substituents are as described
below for non-aromatic heterocyclic rings. Preferably,
Ring C is unsubstituted or substituted with an electron
15 withdrawing group. Suitable electron withdrawing groups
include -CN, alkylsulfonyl, carboxamido, carboxylic alkyl
esters, -NO₂ and halogens (e.g., -Br and -Cl).

Alternatively, Ring C is substituted with a group selected
from -CH₂-NR¹¹R¹², -CH₂-OR¹¹, -CH₂-NH-CO-NR¹¹R¹², -CH₂-O-CO-NR¹¹R¹².
20 R^{11} and R^{12} are independently -H, an aliphatic group a
substituted aliphatic group, an aromatic group, a
substituted aromatic group, -NHC(O)-O-(aliphatic group), or
NHC(O)-O-(aromatic group). In addition, R^{11} and R^{12} , taken
together with the nitrogen atom to which they are bonded,
25 can form a non-aromatic heterocyclic ring.


Examples of suitable tricyclic rings systems
represented by Structural Formula (IV) are provided by
Structural Formula (V)-(VIII), shown below:




(V)



(VI)



(VII)



(VIII)

X_1 is a chemical bond, $-S-$, $-CH_2-$ or $-CH_2S-$.

Preferably, X_1 is $-S-$ in Structural Formulas (V) and (VII).


- 5 Preferably, X_1 is $-CH_2S-$ in Structural Formulas (VI) and (VIII).

W is $-H$ or an electron withdrawing group, as described above for Structural Formula (IV). A preferred electron withdrawing group is $-CN$.


- 10 W_a is a group selected from $-CH_2-NR^{11}R^{12}$, $-CH_2-OR^{11}$, $-CH_2-NH-CO-NR^{11}R^{12}$ or $-CH_2-O-CO-NR^{11}R^{12}$. R^{11} and R^{12} are as defined in Structural Formula (IV).

Ring A and Ring B in Structural Formulas (V)-(VIII) are as described above in Structural Formula (IV).


- 15 Other examples of suitable tricyclic ring systems represented by Structural Formula (IV) are shown below in Structural Formulas (IX)-(XII), (XIIa), (XIIb) and (XIIc):




(IX)




(X)




(XI)




(XII)



(XIIa)



(XIIb)



(XIIc)

Rings A-C in Structural Formulas (IX)-(XII), (XIIa),
5 (XIIb) and (XIIc) are as described for Structural Formula
(IV).








R_z is an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzylic group or a substituted benzylic group.

Preferably, R_z is a substituted C1-C20 aliphatic group, a C10-C20 aliphatic group, an aromatic group, a substituted aromatic group, a benzylic group or a substituted benzylic group. In one example, R_z is $-(CH_2)_s-COOH$, $-(CH_2)_s-COOR^{3c}$ or $-(CH_2)_s-C(O)-NR^{31}R^{32}$.

s is an integer from zero to about 3.






10 R^{30} , R^{31} and R^{32} are independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, $-NHC(O)-O-(\text{aliphatic group})$, $-NHC(O)-O-(\text{aromatic group})$ or $-NHC(O)-O-(\text{non-aromatic heterocyclic group})$. In addition, R^{31} and R^{32} , taken
15 together with the nitrogen atom to which they are bonded, can form a non-aromatic heterocyclic ring.




Preferred examples of tricyclic ring systems represented by Structural Formulas (IX)-(XII), (XIIa), (XIIb) and (XIIc) are shown below in Structural Formulas
20 (XIII)-(XVI), (XVIa), (XVIb) and (XVIc):



V is W or W_b , which are as described above for Structural Formula (V) - (VIII).

In another preferred embodiment, Z is a tricyclic ring system comprising one or more heteroaromatic groups fused to a seven or eight membered cycloalkyl group or to a non-aromatic heterocyclic ring. Examples are represented by Structural Formulas (XVII) - (XXI), (XXIa), (XXIb) and (XXIc):






Ring A in Structural Formulas (XVII)-(XXI), (XXIa),
 (XXIb) and (XXIc) is a substituted or unsubstituted
 5 aromatic group.


Ring B in Structural Formulas (XVII)-(XXI), (XXIa),
 (XXIb) and (XXIc) is a substituted or unsubstituted
 heteroaryl group.

W_b is -H, -CN, $-\text{CH}_2-\text{NR}^{11}\text{R}^{12}$, $-\text{CH}_2-\text{OR}^{11}$, $-\text{CH}_2-\text{NH}-\text{CO}-\text{NR}^{11}\text{R}^{12}$,
 10 $-\text{CH}_2-\text{O}-\text{CO}-\text{NR}^{11}\text{R}^{12}$. R^{11} and R^{12} are as defined above for
 Structural Formula (IV).

In yet another preferred embodiment, the antagonist of
 chemokine function is a compound represented by Structural
 Formula (XXII and (XXIII):



(XXII)



(XXIII)

In Structural Formulas (XXII) and (XXIII), X_1 is as defined above for Structural Formulas (V) and (VI); n is an integer from two to five; W is $-H$, $-CN$, alkylsulfonyl, carboxamido or carboxyalkyl.

In Structural Formulas (XXII) and (XXIII), Ring A is substituted with R_8 and R_9 , wherein R_8 and R_9 are independently $-H$, a halogen, alkoxy or alkyl, or, taken together with ring A, form a naphthyl group. M is $>N(\text{alkanoyl})$, $>N(\text{aroyl})$, $>N(\text{aralkoyl})$, $>N(\text{alkyl})$, $>N(\text{aralkyl})$, $>N(\text{cycloalkyl})$, $>C(OH)(\text{aryl})$ or $>CH(\text{heteroaryl})$.

The present invention also includes novel compounds represented by Structural Formulas (II) and (III).

In one embodiment, the novel compounds are represented by Structural Formulas (II) and (III) wherein Z is a group in which one or more heteroaromatic rings are fused to a cycloalkyl ring or a non-aromatic heterocyclic ring. Each ring in Z is independently substituted or unsubstituted.

Examples of suitable Z groups are represented by Structural Formulas (XVII)-(XXI), (XXIa), (XXIb) and (XXIc). Ring A, Ring B, M, W_b, R₁, R₂, R_c and n are as described in Structural Formulas (XVII) through (XXIc).

- 5 In another embodiment, the novel compounds are represented by Structural Formulas (II) and (III) have a Z group represented by Structural Formulas (V) and (VI). At least one of Ring A or Ring B is substituted. M, W, R₁, R₂ and n are as described in Structural Formulas (V) and (VI).
- 10 In another embodiment, the novel compounds represented by Structural Formulas (II) and (III) have a Z group represented by Structural Formulas (VII) and (VIII). Ring A, Ring B, M, W_a, R₁, R₂ and n are as described in Structural Formulas (VII) and (VIII).
- 15 In another embodiment, the novel compounds represented by Structural Formulas (II) and (III) have a Z group represented by Structural Formulas (XIII)-(XVI), (XVIa), (XVIb) and (XVIc). Ring A, Ring B, M, R₁, R₂, R_c and n are as described in Structural Formulas (XIII) through (XVIc).
- 20 V is -CN, -CH₂-NR¹¹R¹², -CH₂-OR¹¹, -CH₂-NH-CO-NR¹¹R¹², -CH₂-O-CO-NR¹¹R¹². R¹¹ and R¹² are as defined above for Structural Formula (IV).

- In another embodiment, the novel compounds represented by Structural Formulas (II) and (III) have a Z group
- 25 represented by Structural Formula (XVI). Ring A, Ring B, M, R₁, R₂, and n are as described in Structural Formula (XVI). V is -H and R_c is a C10-C20 aliphatic group, a substituted C10-C20 aliphatic group, an aromatic group, a substituted aromatic group, a benzylic group or a
- 30 substituted benzylic group. In one example, R_c is

- (CH₂)_s-COOH, - (CH₂)_s-COOR³⁰ or - (CH₂)_s-C(O)-NR³¹R³², wherein s, R³⁰, R³¹ and R³² are as described above. Preferably, R₂ is an aromatic group, a substituted aromatic group, a benzylic group or a substituted benzylic group.

5 In yet another embodiment, the novel compounds represented by Structural Formula (II) and (III) have a Z group represented by Structural Formulas (XXII) and (XXIII). Ring A, Ring B, M, W, and n are as described in Structural Formulas (XXII) through (XXIII). R_e and R_f are
10 independently a halogen, alkoxy or alkyl, or, taken together with ring A, form a naphthyl group.

Also included in the present invention are physiologically acceptable salts of the compounds represented by Structural Formulas (I) through (XXIII).
15 Salts of compounds containing an amine or other basic group can be obtained, for example, by reacting with a suitable organic or inorganic acid, such as hydrogen chloride, hydrogen bromide, acetic acid, perchloric acid and the like. Compounds with a quaternary ammonium group also
20 contain a counteranion such as chloride, bromide, iodide, acetate, perchlorate and the like. Salts of compounds containing a carboxylic acid or other acidic functional group can be prepared by reacting with a suitable base, for example, a hydroxide base. Salts of acidic functional
25 groups contain a countercation such as sodium, potassium and the like.







As used herein, aliphatic groups include straight chained, branched or cyclic C₁-C₈ hydrocarbons which are completely saturated or which contain one or more units of
30 unsaturation.

- An "alkyl group" is a saturated aliphatic group, as defined above. The term "alkoxy" refers to an alkyl ether chain with an alkyl group. "Alkanoyl" refers to alkyl substituted carbonyl; "aralkanoyl" refers to
- 5 phenyl-alkyl-CO- and "aroyl" refers to arylcarbonyl including benzoyl, naphthoyl and the like. The term "halogen" means fluoro, chloro, bromo and iodo. The term "aryl", as opposed to the term "aromatic group", means phenyl. The term "substituted phenyl" means aryl
- 10 substituted by alkyl, halogen, alkoxy, nitro, amino, acetamido, cyano and trifluoromethyl and naphthyl. "Aralkyl" means $-(CH_2)_x$ -phenyl, wherein x is an integer from one to four including benzyl. It is noted that the terms "aromatic group", "carbocyclic aromatic group" and
- 15 "heterocyclic aromatic group" are defined below and have different meanings from the term "aryl".


- Aromatic groups include carbocyclic aromatic groups such as phenyl, 1-naphthyl, 2-naphthyl, 1-anthracyl and 2-anthacyl, and heterocyclic aromatic groups such as
- 20 N-imidazolyl, 2-imidazole, 2-thienyl, 3-thienyl, 2-furanyl, 3-furanyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidy, 4-pyrimidyl, 2-pyranyl, 3-pyranyl, 3-pyrazolyl, 4-pyrazolyl, 5-pyrazolyl, 2-pyrazinyl, 2-thiazole, 4-thiazole, 5-thiazole, 2-oxazolyl, 4-oxazolyl and
- 25 5-oxazolyl.

- Aromatic groups also include fused polycyclic aromatic ring systems in which a carbocyclic aromatic ring or heteroaryl ring is fused to one or more other heteroaryl rings. Examples include 2-benzothienyl, 3-benzothienyl,
- 30 2-benzofuranyl, 3-benzofuranyl, 2-indolyl, 3-indolyl, 2-quinolinyl, 3-quinolinyl, 2-benzothiazole,

2-benzooxazole, 2-benzimidazole, 2-quinolinyl,
3-quinolinyl, 1-isoquinolinyl, 3-quinolinyl, 1-isoindolyl,
3-isoindolyl, and acridintyl. Also included within the
scope of the term "aromatic group", as it is used herein,
5 is a group in which one or more carbocyclic aromatic rings
and/or heteroaromatic rings are fused to a cycloalkyl or
non-aromatic heterocyclic ring. Examples include decalin,
phthalimido, benzodiazepines, benzooxazepines,
benzooxazines, phenothiazines, and groups represented by
10 the following structural formulas:



or



Non-aromatic heterocyclic rings are non-aromatic carbocyclic rings which include one or more heteroatoms such as nitrogen, oxygen or sulfur in the ring. The ring can be five, six, seven or eight-membered. Examples

5 include 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahydrothiophenyl, 3-tetrahydrothiophenyl, 2-morpholino, 3-morpholino, 4-morpholino, 2-thiomorpholino, 3-thiomorpholino, 4-thiomorpholino, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 1-piperazinyl,

10 2-piperazinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl and 4-thiazolidinyl.

"Heterocyclic ring", as opposed to "heteroaryl group" and "non-aromatic heterocyclic ring", is defined as imidazole, benzimidazole, pyridine, pyrimidine, thiazole,

15 benzothiazole, thienyl, benzothienyl. It is noted further the terms "heterocyclic aromatic group" and "non-aromatic heterocyclic ring" are defined above and have different meanings from the term "heterocyclic ring".

Suitable substituents on an alkyl, aliphatic,

20 aromatic, non-aromatic heterocyclic ring or benzyl group include, for example, -OH, halogen (-Br, -Cl, -I and -F) -O(aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic group), -CN, -NC₂, -COOH, -NH₂, -NH(aliphatic group, substituted aliphatic,

25 benzyl, substituted benzyl, aromatic or substituted aromatic group), -N(aliphatic group, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic group), -COO(aliphatic group, substituted aliphatic, benzyl, substituted benzyl, aromatic or

30 substituted aromatic group), -CONH₂, -CONH(aliphatic,

substituted aliphatic group, benzyl, substituted benzyl, aromatic or substituted aromatic group)), -SH, -S(aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic group) and

5 -NH-C(=NH)-NH₂. A substituted non-aromatic heterocyclic ring, benzylic group or aromatic group can also have an aliphatic or substituted aliphatic group as a substituent. A substituted alkyl or aliphatic group can also have a non-aromatic heterocyclic ring, benzyl, substituted benzyl,

10 aromatic or substituted aromatic group as a substituent. A substituted non-aromatic heterocyclic ring can also have =O, =S, =NH or =N(aliphatic, aromatic or substituted aromatic group) as a substituent. A substituted aliphatic, substituted aromatic, substituted non-aromatic heterocyclic

15 ring or substituted benzyl group can have more than one substituent.

In the structural formulas depicted herein, the single or double bond by which a chemical group or moiety is connected to the remainder of the molecule or compound is

20 indicated by the following symbol:



For example, the corresponding symbol in Structural Formula (V) or (VIII) indicates that the tricyclic ring system, which represents Z in Structural Formula (I), is connected

25 to the alkylene group in Structural Formula (I) by a single covalent bond between the alkylene group and the ring carbon in Ring C which is bonded to W.

A "subject" is preferably a mammal, such as a human, but can also be an animal in need of veterinary treatment, e.g., domestic animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, sheep, pigs, horses, and the like) and laboratory animals (e.g., rats, mice, guinea pigs, and the like).

A "therapeutically effective amount" of a compound is an amount which results in the inhibition of one or more processes mediated by the binding of a chemokine to a receptor in a subject with a disease associated with aberrant leukocyte recruitment and/or activation. Examples of such processes include leukocyte migration, integrin activation, transient increases in the concentration of intracellular free calcium $[Ca^{2+}]$, and granule release of proinflammatory mediators. Alternatively, a "therapeutically effective amount" of a compound is a quantity sufficient to achieve a desired therapeutic and/or prophylactic effect, such as an amount which results in the prevention of or a decrease in the symptoms associated with a disease associated with aberrant leukocyte recruitment and/or activation.

The amount of compound administered to the individual will depend on the type and severity of the disease and on the characteristics of the individual, such as general health, age, sex, body weight and tolerance to drugs. It will also depend on the degree, severity and type of disease. The skilled artisan will be able to determine appropriate dosages depending on these and other factors. Typically, a therapeutically effective amount of the compound can range from about 0.1 mg per day to about 100 mg per day for an adult. Preferably, the dosage ranges

from about 1 mg per day to about 100 mg per day. An antagonist of chemokine receptor function can also be administered in combination with one or more additional therapeutic agents, e.g. theophylline, β -adrenergic
5 bronchodilators, corticosteroids, antihistamines, antiallergic agents, immunosuppressive agents (e.g., cyclosporin A, FK-506, prednisone, methylprednisolone) and the like.

The compound can be administered by any suitable
10 route, including, for example, orally in capsules, suspensions or tablets or by parenteral administration. Parenteral administration can include, for example, systemic administration, such as by intramuscular, intravenous, subcutaneous, or intraperitoneal injection.
15 The compound can also be administered orally (e.g., dietary), topically, by inhalation (e.g., intrabronchial, intranasal, oral inhalation or intranasal drops), or rectally, depending on the disease or condition to be treated. Oral or parenteral administration are preferred
20 modes of administration.

The compound can be administered to the individual in conjunction with an acceptable pharmaceutical or physiological carrier as part of a pharmaceutical composition for treatment of HIV infection, inflammatory
25 disease, or the other diseases discussed above. Formulation of a compound to be administered will vary according to the route of administration selected (e.g., solution, emulsion, capsule). Suitable carriers may contain inert ingredients which do not interact with the
30 compound. Standard formulation techniques can be employed, such as those described in Remington's Pharmaceutical

Sciences, Mack Publishing Company, Easton, PA. Suitable carriers for parenteral administration include, for example, sterile water, physiological saline, bacteriostatic saline (saline containing about 0.9% mg/ml benzyl alcohol), phosphate-buffered saline, Hank's solution, Ringer's-lactate and the like. Methods for encapsulating compositions (such as in a coating of hard gelatin or cyclodextran) are known in the art (Baker, et al., "Controlled Release of Biological Active Agents", John Wiley and Sons, 1986).

The activity of compounds of the present invention can be assessed using suitable assays, such as receptor binding assays and chemotaxis assays. For example, as described in the Exemplification Section, small molecule antagonists of RANTES and MIP-1 α binding have been identified utilizing THP-1 cells which bind RANTES and chemotax in response to RANTES and MIP-1 α as a model for leukocyte chemotaxis. Specifically, a high through-put receptor binding assay, which monitors ^{125}I -RANTES and ^{125}I -MIP-1 α binding to THP-1 cell membranes, was used to identify small molecule antagonists which block binding of RANTES and MIP-1 α . Compounds of the present invention can also be identified by virtue of their ability to inhibit the activation steps triggered by binding of a chemokine to its receptor, such as chemotaxis, integrin activation and granule mediator release. They can also be identified by virtue of their ability to block RANTES and MIP-1 α mediated HL-60, T-cell, peripheral blood mononuclear cell, and eosinophil chemotactic response.

The compounds disclosed herein can be prepared accordingly to the schemes shown in Figures 1-3. The schemes are described in greater detail below.

Figure 1 is a schematic showing the preparation of the 5 compounds represented by Structural Formula (I).

L^1 , L^2 and L^3 in Figure 1 are suitable leaving groups such as halogen; p-toluene sulfonate, mesylate, alkoxy and phenoxy. The other symbols are as defined above.

The reduction reaction in Step 1 of Figure 1 is 10 performed with a reducing agent such as or sodium borohydride or lithium aluminum hydride (LAH) in an inert solvent such as methanol or tetrahydrofuran (THF). The reaction is carried out at temperatures ranging from 0°C up to the reflux temperature and for 5 minutes to 72 h.

15 Compounds represented by formula II in Figure 1 can be prepared by procedures disclosed in JP 61/152673, U.S. Patent 5089496, WO 89/10369, WO 92/20681 and WO 93/02081, the entire teachings of which are incorporated herein by reference.

20 A chlorination reaction in step 2 of Figure 1 can be performed with reagents such as thionyl chloride. The reaction can be carried out in an inert solvent such as methylene chloride at 0°C up to the reflux temperature for 5 minutes to 72 h. The hydroxy group can be also converted 25 to other leaving groups by methods familiar to those skilled in the art.

The cyanation reaction in step 3 of Figure 1 can be carried out using reagents such as copper cyanide, silver cyanide or sodium cyanide in an inert solvent such as 30 benzene or toluene. Reaction temperatures range from 0°C up to the reflux temperature for 5 minutes to 72 h. Compounds

represented by Formula V in Figure 1 can also be prepared by the procedures described in J. Med. Chem. 1994, 37, 804-810 and U.S. Patent 5672611, the entire teachings of which are incorporated herein by reference.

5 The alkylation reactions in steps 4 and 5 of Figure 1 can be carried out in a solvent such as acetone, methyl ethyl ketone, ethyl acetate, toluene, tetrahydrofuran (THF) or dimethylformamide (DMF) in the presence of a base such as potassium carbonate or sodium hydride and a catalyst
10 such as an alkali metal iodide (when necessary). The reaction temperature can range from room temperature up to the reflux temperature and for 5 minutes to 72 h.

 The product of the synthetic scheme shown in Figure 1 can be decyanated using a reducing agent such as lithium
15 aluminum hydride (LAH) in an inert solvent such as ether or tetrahydrofuran (THF) at 0°C up to the reflux temperature for the solvent used for 5 minutes to 72 h.

 Figure 2 is a schematic showing the preparation of the compounds represented by Structural Formula (I) and II),
20 wherein Z is represented by Structural Formulas (IV) and wherein Ring A in Z is substituted with
 - (CH₂)_t-COOH, - (CH₂)_t-COOR²⁰ or - (CH₂)_t-C(O)-NR²¹R²².

 In Figure 2, the hydrolysis reaction may be carried out in a mixture of aqueous alkali metal hydroxide solution
25 and a solvent such as methanol, ethanol, tetrahydrofuran (THF) or dioxane at room temperature up to the reflux temperature for the solvent used for 5 minutes to 72 h.
 The acylation reaction can be carried out using dicyclohexylcarbodiimide (DCC) or (1-ethyl-3-(3-
30 dimethylaminopropyl)carbodiimide (DEC) in a solvent such as tetrahydrofuran (THF), dimethylformamide (DMF) or methylene

chloride in the presence of a base such as pyridine or triethylamine (when necessary) at temperatures of 0 to 100°C for 5 minutes to 72 h.

Compounds represented by Structural Formulas (I) and (II), wherein Z is represented by Structural Formulas (XVI), X is $-\text{CO}-\text{N}(\text{R}_c)-$ and R_c is $-(\text{CH}_2)_s-\text{COOH}$, $-(\text{CH}_2)_s-\text{COOR}^{30}$ or $-(\text{CH}_2)_s-\text{C}(\text{O})-\text{NR}^{31}\text{R}^{32}$ can be prepared by suitable modification of the scheme shown in Figure 1. One modification utilizes the starting material shown in Figure 1, wherein X is $-\text{CO}-\text{NH}-$. The amide is then alkylated with $\text{L}^3-(\text{CH}_2)_s-\text{COOR}^{30}$ using the alkylation procedures described above. L^3 is a suitable leaving group. The remainder of the synthesis is as described in Figures 1 and 2.

Figure 3 is a schematic showing the preparation of the compounds represented by Structural Formula (I) and (II), wherein Z is represented by Structural Formulas (VIII) and (XIII)-(XVI) and wherein V is W_a .

The reduction of the cyano group to an amine in Figure 3 can be carried out using metal hydrides or by catalytic reduction processes. Suitable reducing agents include lithium aluminum hydride (LAH), diisobutyl aluminum hydride (DIBAL-H), borane-methyl sulfide complex or sodium borohydride. The reduction can be carried out in an inert solvent such as ether, tetrahydrofuran (THF), methylene chloride or methanol at -78°C up to the reflux temperature for 5 minutes to 72 h. It is also possible to isolate the corresponding imine intermediate, which can be converted to the amine using similar reduction processes.

Although Figures 1-3 show the preparation of compounds in which Rings A and B are phenyl rings, analogous compounds with heteroaryl groups for Rings A and B can be

prepared by using the starting materials with heteroaryl groups in the corresponding positions, which can be prepared according to methods disclosed in JP 61/152673, U.S. Patent 5089496, WO 89/10369, WO 92/20681 and WO 5 93/02081.

The invention is illustrated by the following examples which are not intended to be limiting in any way.

EXEMPLIFICATION

Example 1 - Preparation of 4-(4-Chlorophenyl)-1-[3-(5-cyano-10 5H-dibenzo[a,d]cycloheptene-5-yl)propyl]piperidin-4-ol

To a solution of 5H-dibenzo[a,d]cycloheptene-5-carbonitrile (described in J. Med Chem. 1994, 37, 804-810) (500mg) in DMF (10ml) were added 60% sodium hydride (110mg) and 1-bromo-3-chloropropane (0.30ml) and the 15 mixture was stirred at room temperature for 1 hours. Water and ethyl acetate were added to the reaction mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried over magnesium sulfate. The solvent was distilled off under reduced pressure to 20 give 5-(3-chloropropyl)-5H-dibenzo[a,d]cycloheptene-5-carbonitrile. Without purification, to a solution obtained chloride in DMF (10ml) were added 4-(4-chlorophenyl)-4-hydroxypiperidine (650mg), potassium carbonate (950mg), and potassium iodide (50mg) and the 25 mixture was stirred at 70°C for 24 hours. Water and ethyl acetate were added to the reaction mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried over magnesium sulfate. The solvent was distilled off under reduced pressure. The

residue was purified by silica gel chromatography eluting with ethyl acetate-hexane (1:1) to give the titled compound (700mg). ¹H-NMR (CDCl₃) δ: 1.22-1.34 (2H,m), 1.60-1.80 (3H,m), 1.93-1.99 (2H,m), 2.16-2.28 (6H,m), 5 2.56-2.60 (2H,m), 6.98 (2H,s), 7.25-7.47 (10H,m), 8.00-8.03 (2H,m). MS m/z: 469 (M+1)

Example 2 - Preparation of 4-(4-Chlorophenyl)-1-[3-(5-cyano-10,11-dihydro-5H-dibenzo[a,d]cycloheptene-5-yl)propyl]piperidin-4-ol

10 Following the procedure of example 1, but replacing 5H-dibenzo[a,d]cycloheptene-5-carbonitrile with 10,11-dihydro-5H-dibenzo[a,d]cycloheptene-5-carbonitrile, the titled compound was prepared. ¹H-NMR (CDCl₃) δ: 1.43-1.49 (2H,m), 1.61-1.66 (2H,m), 1.93-2.02 (3H,m), 15 2.24-2.32 (4H,m), 2.48-2.62 (4H,m), 2.96-3.06 (2H,m), 3.35-3.45 (2H,m), 7.11-7.41 (10H,m), 7.93-7.97 (2H,m). MS m/z: 471 (M+1)

Example 3 - Preparation of 4-(4-Chlorophenyl)-1-[3-(11-cyano-6,11-dihydrodibenz[b,e]oxepin-11-yl)propyl]piperidin-20 4-ol

Following the procedure of example 1, but replacing 5H-dibenzo[a,d]cycloheptene-5-carbonitrile with 6,11-dihydrodibenz[b,e]oxepin-11-carbonitrile, the titled compound was prepared. ¹H-NMR (CDCl₃) δ: 1.37-1.68 (5H,m), 25 1.99-2.09 (2H,m), 2.24-2.50 (5H,m), 2.65-2.69 (2H,m), 2.78-2.85 (1H,m), 5.03 (1H,d), 5.45 (1H,d), 7.02-7.43 (10H,m), 7.82-7.86 (1H,m), 7.95-8.00 (1H,m). MS m/z: 473 (M+1)

Example 4 - Preparation of 1-[3-(11-Cyano-6,11-dihydrodibenz[b,e]oxepin-11-yl)propyl]-4-(4-fluorophenyl)piperidin-4-ol

Following the procedure of example 3, but replacing
5 4-(4-chlorophenyl)-4-hydroxypiperidine with
4-(4-fluorophenyl)-4-hydroxypiperidine, the titled
compound was prepared. ¹H-NMR (CDCl₃) δ: 1.40-1.68(4H,m),
1.88-2.08(3H,m), 2.29-2.50(5H,m), 2.63-2.67(2H,m),
2.77-2.84(1H,m), 5.03(1H,d), 5.44(1H,d), 6.95-7.46(10H,m),
10 7.81-7.85(1H,m), 7.94-7.99(1H,m). MS m/z: 457(M+1)

Example 5 - Preparation of 4-(4-Chlorophenyl)-1-[3-(11-cyano-6,11-dihydro-2-fluorodibenz[b,e]oxepin-11-yl)propyl]piperidin-4-ol

Following the procedure of example 1, but replacing
15 5H-dibenzo[a,d]cycloheptene-5-carbonitrile with
6,11-dihydro-2-fluorodibenz[b,e]oxepin-11-carbonitrile, the
titled compound was prepared. ¹H-NMR (CDCl₃) δ:
1.37-1.69(5H,m), 1.98-2.09(2H,m), 2.25-2.48(5H,m),
2.65-2.70(2H,m), 2.78-2.87(1H,m), 5.01(1H,d), 5.42(1H,d),
20 6.99-7.11(3H,m), 7.25-7.43(6H,m), 7.54-7.59(1H,m),
7.92-7.95(1H,m). MS m/z: 491(M+1)

Example 6 - Preparation of 1-[3-(2-Bromo-11-cyano-6,11-dihydrodibenz[b,e]oxepin-11-yl)propyl]-4-(4-chlorophenyl)piperidin-4-ol

25 Following the procedure of example 1, but replacing
5H-dibenzo[a,d]cycloheptene-5-carbonitrile with
2-bromo-6,11-dihydrodibenz[b,e]oxepin-11-carbonitrile, the
titled compound was prepared. ¹H-NMR (CDCl₃) δ:

1.37-1.69 (5H,m), 1.97-2.09 (2H,m), 2.24-2.48 (5H,m),
2.66-2.85 (3H,m), 5.00 (1H,d), 5.43 (1H,d), 6.97-7.02 (2H,m),
7.24-7.46 (7H,m), 7.91-7.95 (2H,m).

MS m/z: 551, 553 (M+1)

5 Example 7 - Preparation of 4-(4-Chlorophenyl)-1-[3-(11-cyano-6,11-dihydro-2-methyldibenz[b,e]oxepin-11-yl)propyl]piperidin-4-ol

Following the procedure of example 1, but replacing
5H-dibenzo[a,d]cycloheptene-5-carbonitrile with
10 6,11-dihydro-2-methyldibenz[b,e]oxepin-11-carbonitrile, the
titled compound was prepared. ¹H-NMR (CDCl₃) δ:

1.40-1.70 (5H,m), 1.98-2.09 (2H,m), 2.25-2.52 (8H,m),
2.68-2.73 (2H,m), 2.81-2.90 (1H,m), 5.00 (1H,d), 5.44 (1H,d),
6.98-7.43 (9H,m), 7.63 (1H,d), 7.94-7.98 (1H,m). MS m/z:

15 487 (M+1)

Example 8 - Preparation of 4-(4-Chlorophenyl)-1-[3-(11-cyano-3,4-dichloro-6,11-dihydro-dibenz[b,e]oxepin-11-yl)propyl]piperidin-4-ol

Following the procedure of example 1, but replacing
20 5H-dibenzo[a,d]cycloheptene-5-carbonitrile with
3,4-dichloro-6,11-dihydrodibenz[b,e]oxepin-11-carbonitrile,
the titled compound was prepared. ¹H-NMR (CDCl₃) δ:

1.40-1.71 (5H,m), 2.00-2.10 (2H,m), 2.28-2.50 (5H,m),
2.65-2.85 (3H,m), 5.04 (1H,d), 5.46 (1H,d), 6.99-7.03 (1H,m),

25 7.26-7.44 (7H,m), 7.91-7.95 (2H,m). MS m/z: 541 (M+1)

Example 9 - Preparation of 4-(4-Chlorophenyl)-1-[3-(11-cyano-6,11-dihydro-2,3-methylenedioxydibenz[b,e]oxepin-11-yl)propyl]piperidin-4-ol

Following the procedure of example 1, but replacing
5 5H-dibenzo[a,d]cycloheptene-5-carbonitrile with
6,11-dihydro-2,3- methylenedioxydibenz[b,e]oxepin-
11-carbonitrile, the titled compound was prepared. ¹H-NMR
(CDCl₃) δ: 1.60-1.90 (5H,m), 2.30-2.50 (2H,m),
2.80-3.30 (8H,m), 5.05 (1H,d), 5.45 (1H,d), 6.02 (2H,brd),
10 6.68 (1H,s), 6.97-7.01 (1H,m), 7.26-7.43 (7H,m),
7.83-7.87 (2H,m). MS m/z: 517 (M+1)

Example 10 - Preparation of 4-(4-Chlorophenyl)-1-[3-(11-cyano-6,11-dihydrodibenzo[b,e]thiepin-11-yl)propyl]piperidin-4-ol

15 Following the procedure of example 1, but replacing
5H-dibenzo[a,d]cycloheptene-5-carbonitrile with
6,11-dihydrodibenzo[b,e]thiepin-11-carbonitrile, the titled
compound was prepared. ¹H-NMR (CDCl₃) δ: 1.63-1.76 (5H,m),
2.03-2.16 (2H,m), 2.37-2.52 (4H,m), 2.72-2.85 (3H,m),
20 3.03-3.10 (1H,m), 4.10 (1H,d), 4.54 (1H,d), 7.13-7.44 (10H,m),
7.81-7.87 (2H,m). MS m/z: 489 (M+1)

Example 11 - Preparation of 1-[3-(11-Cyano-6,11-dihydrodibenzo[b,e]thiepin-11-yl)propyl]-4-phenylpiperidin-4-ol

25 Following the procedure of example 10, but replacing
4-(4-chlorophenyl)-4-hydroxypiperidine with 4-hydroxy-4-
phenylpiperidine, the titled compound was prepared.

¹H-NMR (CDCl₃) δ: 1.63-1.77(5H,m), 2.02-2.16(2H,m),
2.37-2.52(4H,m), 2.72-2.85(3H,m), 3.03-3.10(1H,m),
4.10(1H,d), 4.55(1H,d), 7.13-7.52(10H,m), 7.81-7.88(2H,m).
MS m/z: 455(M+1)

- 5 Example 12 - Preparation of 4-(4-Bromophenyl)-1-[3-(11-cyano-6,11-dihydrodibenzo[b,e]thiepin-11-yl)propyl]piperidin-4-ol

Following the procedure of example 10, but replacing
4-(4-chlorophenyl)-4-hydroxypiperidine with
10 4-(4-bromophenyl)-4-hydroxypiperidine, the titled compound
was prepared. ¹H-NMR (CDCl₃) δ: 1.64-1.82(5H,m),
2.02-2.12(2H,m), 2.32-2.48(4H,m), 2.69-2.85(3H,m),
2.99-3.09(1H,m), 4.07(1H,d), 4.50(1H,d), 7.11-7.46(10H,m),
7.79-7.86(2H,m). MS m/z: 533, 535(M+1)

- 15 Example 13 - Preparation of 1-[3-(2-Bromo-11-cyano-6,11-dihydrodibenzo[b,e]thiepin-11-yl)propyl]-4-(4-chlorophenyl)piperidin-4-ol

Following the procedure of example 1, but replacing
5H-dibenzo[a,d]cycloheptene-5-carbonitrile with
20 2-bromo-6,11-dihydrodibenzo[b,e]thiepin-11-carbonitrile,
the titled compound was prepared. ¹H-NMR (CDCl₃) δ:
1.63-1.78(5H,m), 2.03-2.14(2H,m), 2.35-2.52(4H,m),
2.72-2.80(3H,m), 3.00-3.10(1H,m), 4.15(1H,brd), 4.50(1H,d),
7.07-7.45(10H,m), 7.73-7.81(1H,m), 7.95(1H,d). MS m/z: 567,
25 569(M+1)

Example 14, 15 - Preparation of 4-(4-Chlorophenyl)-1-[3-(11-cyano-6,11-dihydro-5-oxodibenzo[b,e]thiepin-11-yl)propyl]piperidin-4-ol

Following the procedure of example 1, but replacing
5 5H-dibenzo[a,d]cycloheptene-5-carbonitrile with
6,11-dihydro-5-oxodibenzo[b,e]thiepin-11-carbonitrile, the
titled compound was prepared. The diastereomers were
separated by silica gel chromatography. isomer 1 ¹H-NMR
(CDCl₃) δ: 1.20-1.35(1H,m), 1.63-1.69(4H,m),
10 2.04-2.84(10H,m), 4.21(1H,d), 4.31(1H,d), 7.18-7.65(9H,m),
8.03-8.13(3H,m). MS m/z: 505(M+1) isomer 2 ¹H-NMR (CDCl₃) δ:
1.25-1.38(1H,m), 1.65-2.15(6H,m), 2.28-2.82(8H,m),
4.65(1H,d), 4.82(1H,d), 7.27-7.56(9H,m), 7.92-8.00(3H,m).
MS m/z: 505(M+1)

15 Example 16 - Preparation of 4-(4-Chlorophenyl)-1-[3-(11-cyano-6,11-dihydro-5,5-dioxodibenzo[b,e]thiepin-11-yl)propyl]piperidin-4-ol

Following the procedure of example 1, but replacing
5H-dibenzo[a,d]cycloheptene-5-carbonitrile with
20 6,11-dihydro-5,5-dioxodibenzo[b,e]thiepin-11-carbonitrile,
the titled compound was prepared. ¹H-NMR (CDCl₃) δ:
1.40-2.72(14H,m), 3.08-3.22(1H,m), 4.58(1H,d), 5.58(1H,d),
7.29-7.58(9H,m), 7.99-8.13(3H,m). MS m/z: 521(M+1)

Example 17 - Preparation of 4-(4-Chlorophenyl)-1-[3-(6,11-dihydrodibenzo[b,e]thiepin-11-yl)propyl]piperidin-4-ol

To a solution of 4-(4-chlorophenyl)-1-[3-(11-cyano-6,11-dihydrodibenzo[b,e]thiepin-11-yl)propyl]piperidin-4-ol (430mg) in THF 10ml) was added 1M lithium aluminum hydride THF solution (1.5ml) and the mixture was heated to reflux for 3 hours. The reaction mixture was cooled with ice, water (0.06ml), then 15% aqueous sodium hydroxide (0.06ml), then water (0.18ml) were added carefully. The granular salt was filtered off and the filtrate was distilled off under reduced pressure. The residue was purified by silica gel chromatography eluting with ethyl acetate-hexane (1:1) to give the titled compound (280mg). ¹H-NMR (CDCl₃) δ: 1.55-1.80(4H,m), 2.03-2.16(2H,m), 2.25-2.52(6H,m), 2.72-2.80(2H,m), 3.90(1H,brs), 4.48(1H,brt), 4.68(1H,brs), 6.96-7.45(12H,m). MS m/z: 464 (M+1)

Example 18 - Preparation of 4-(4-Chlorophenyl)-1-[3-(10,11-dihydro-5H-dibenzo[a,d]cycloheptene-5-yl)propyl]piperidin-4-ol

Following the procedure of example 17, but replacing 4-(4-chlorophenyl)-1-[3-(11-cyano-6,11-dihydrodibenzo[b,e]thiepin-11-yl)propyl]piperidin-4-ol with 4-(4-chlorophenyl)-1-[3-(5-cyano-10,11-dihydro-5H-dibenzo[a,d]cycloheptene-5-yl)propyl]piperidin-4-ol, the titled compound was prepared. ¹H-NMR (CDCl₃) δ: 1.40-1.58(2H,m), 1.62-1.71(2H,m), 1.98-2.20(4H,m), 2.30-2.42(4H,m), 2.67-2.78(2H,m), 2.95-3.08(2H,m),

3.30-3.44 (2H,m), 4.01 (1H,t), 7.10-7.46 (12H,m). MS m/z:
446 (M+1)

Example 19 - Preparation of 4-(4-Chlorophenyl)-1-[3-(6,11-dihydrodibenz[b,e]oxepin-11-yl)propyl]piperidin-4-ol

5 Following the procedure of example 17, but replacing
4-(4-chlorophenyl)-1-[3-(11-cyano-6,11-dihydrodibenzo[b,e]thiepin-11-yl)propyl]piperidin-4-ol with
4-(4-chlorophenyl)-1-[3-(11-cyano-6,11-dihydrodibenz[b,e]oxepin-11-yl)propyl]piperidin-4-ol, the titled compound was
10 prepared. ¹H-NMR (CDCl₃) δ: 1.36-1.49 (2H,m),
1.58-1.67 (2H,m), 1.95-2.33 (8H,m), 2.63-2.68 (2H,m),
3.74 (1H,t), 4.95 (1H,d), 5.48 (1H,d), 6.95-7.39 (12H,m). MS
m/z: 448 (M+1)

Example 20 - Preparation of 4-(4-Chlorophenyl)-1-[3-(6,11-dihydro-11-iminodibenzo[b,e]thiepin-11-yl)propyl]
15 piperidin-4-ol

To a solution of 4-(4-chlorophenyl)-1-[3-(11-cyano-6,11-dihydrodibenzo[b,e]thiepin-11-yl)propyl]piperidin-4-ol
(1.92g) in dichloromethane (30ml) at -78°C was added 1M
20 diisobutyl aluminum hydride dichloromethane solution
(10ml). The reaction mixture was warmed to room
temperature, and stirred for 30 minutes. Water and
dichloromethane were added to the reaction mixture, the
organic layer was separated and washed with saturated
25 aqueous sodium chloride, and dried over magnesium sulfate.
The solvent was distilled off under reduced pressure. The
residue was purified by silica gel chromatography eluting
with ethyl acetate to give the titled compound (1.16g).

¹H-NMR (CDCl₃) δ: 1.65-1.80 (5H, m), 2.02-2.18 (2H, m),
2.45-2.60 (6H, m), 2.78-2.86 (2H, m), 3.82 (1H, d), 4.25 (1H, d),
7.05-7.45 (12H, m), 8.28 (1H, brs). MS m/z: 491 (M+1)

Example 21 - Preparation of 4-(4-Chlorophenyl)-1-[3-(11-
5 aminomethyl-6,11-dihydrodibenzo[b,e]thiepin-11-
yl)propyl]piperidin-4-ol

To a solution of 4-(4-chlorophenyl)-1-[3-(6,11-dihydro-
11-iminodibenzo[b,e]thiepin-11-yl)propyl]piperidin-4-ol
(600mg) in methanol (15ml) was sodium borohydride (220mg),
10 and the mixture was stirred at room temperature for 10
hours. The solvent was distilled off under reduced
pressure. Water and ethyl acetate were added to the
reaction mixture, the organic layer was separated and
washed with saturated aqueous sodium chloride, and dried
15 over magnesium sulfate. The solvent was distilled off under
reduced to give the titled compound (600mg). MS
m/z: 493 (M+1)

Example 22 - Preparation of Phenyl N-[2-[3-[4-(4-
chlorophenyl)-4-hydroxypiperidino]propyl]-2-
20 (6,11-dihydrodibenzo[b,e]thiepin-11-yl)ethyl] carbamate

To a solution of 4-(4-chlorophenyl)-1-[3-(11-
aminomethyl-6,11-dihydrodibenzo[b,e]thiepin-11-
yl)propyl] piperidin-4-ol (610mg) in THF (20ml) was
triethylamine (0.2ml) and phenyl chlorocarbonate (0.16ml)
25 at 0°C, and the mixture was stirred for 1 hours. Water and
ethyl acetate were added to the reaction mixture, the
organic layer was separated and washed with saturated
aqueous sodium chloride, and dried over magnesium sulfate.

The solvent was distilled off under reduced pressure. The residue was purified by silica gel chromatography eluting with ethyl acetate to give the titled compound (400mg).

¹H-NMR (CDCl₃) δ: 1.40-2.90 (15H,m), 4.05-4.12 (2H,m),
5 4.38 (1H,d), 4.50-4.60 (1H,m), 5.98 (1H,brs),
6.96-7.54 (17H,m). MS m/z: 613 (M+1)

Example 23 - Preparation of 1-[2-[3-[4-(4-chlorophenyl)-4-hydroxypiperidino]propyl]-2-(6,11-dihydrodibenzo[b,e]thiepin-11-yl)ethyl]-3-

10 (hydroxypropyl)urea

To a solution phenyl N-[2-[3-[4-(4-chlorophenyl)-4-hydroxypiperidino]propyl]-2-(6,11-dihydrodibenzo[b,e]thiepin-11-yl)ethyl] carbamate (300mg) in DMF (10ml) were added 3-amino-1-propanol (70mg),

15 potassium carbonate (130mg) and the mixture was stirred at room temperature for 16 hours. Water and ethyl acetate were added to the reaction mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried over magnesium sulfate. The solvent was
20 distilled off under reduced pressure. The residue was purified by silica gel chromatography eluting with ethyl acetate-methanol (9:1) to give the titled compound (200mg).

¹H-NMR (CDCl₃) δ: 1.40-1.70 (6H,m), 2.01-2.08 (2H,m),
2.30-2.63 (8H,m), 3.12 (2H,q), 3.42 (2H,t), 4.00-4.12 (2H,m),
25 4.22-4.28 (2H,m), 4.82 (1H,brt), 4.99 (1H,brs),
6.98-7.45 (12H,m). MS m/z: 594 (M+1)

Example 24 - Preparation of 4-(4-Chlorophenyl)-1-[3-(10,11-dihydro-5H-dibenzo[a,d]cycloheptene-5-yl)-3-propioyl]piperidin-4-ol

To a solution 10,11-dihydro-5H-dibenzo[a,d]
5 cycloheptene-5-carbonitrile (500mg) in THF (5ml) was added 1.6M n-butyl lithium hexane solution (1.8ml) at 0°C. The mixture was warmed to room temperature, and stirred for 20 minutes. To the reaction mixture cooled to 0°C was added ethyl 3-(4-(4-chlorophenyl)-4-hydroxypiperidine-
10 1-yl)propionate (310mg) dropwise as THF solution (2ml), and the mixture was warmed to room temperature, and stirred for 30 minutes. Water and ethyl acetate were added to the reaction mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried
15 over magnesium sulfate. The solvent was distilled off under reduced pressure. The residue was purified by silica gel chromatography eluting with ethyl acetate-hexane (1:1) to give the titled compound (380mg). ¹H-NMR (CDCl₃) δ:
1.57-1.62(2H,m), 1.91-2.01(3H,m), 2.27-2.84(10H,m),
20 3.30-3.44(2H,m), 4.65(1H,s), 7.10-7.38(12H,m).
MS m/z: 460 (M+1)

Examples 28 - 59 can be prepared by methods set forth in the schemes in Figure 1-3 and the procedures described above.

Example 60

Membrane Preparations for Chemokine Binding and Binding Assays

Membranes were prepared from THP-1 cells (ATCC #TIB202).

- 5 Cells were harvested by centrifugation, washed twice with PBS (phosphate-buffered saline), and the cell pellets were frozen at -70 to -85°C. The frozen pellet was thawed in ice-cold lysis buffer consisting of 5 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethane-sulfonic acid) pH 7.5, 2
- 10 mM EDTA (ethylenediaminetetraacetic acid), 5 µg/ml each aprotinin, leupeptin, and chymostatin (protease inhibitors), and 100 µg/ml PMSF (phenyl methane sulfonyl fluoride - also a protease inhibitor), at a concentration of 1 to 5 x 10⁷ cells/ml. This procedure results in cell
- 15 lysis. The suspension was mixed well to resuspend all of the frozen cell pellet. Nuclei and cell debris were removed by centrifugation of 400 x g for 10 minutes at 4°C. The supernatant was transferred to a fresh tube and the membrane fragments were collected by centrifugation at
- 20 25,000 x g for 30 minutes at 4°C. The supernatant was aspirated and the pellet was resuspended in freezing buffer consisting of 10 mM HEPES pH 7.5, 300 mM sucrose, 1 µg/ml each aprotinin, leupeptin, and chymostatin, and 10 µg/ml PMSF (approximately 0.1 ml per each 10⁸ cells). All clumps
- 25 were resolved using a minihomogenizer, and the total protein concentration was determined using a protein assay kit (Bio-Rad, Hercules, CA, cat #500-0002). The membrane solution was then aliquoted and frozen at -70 to -85°C until needed.

Binding Assays utilized the membranes described above. Membrane protein (2 to 20 μ g total membrane protein) was incubated with 0.1 to 0.2 nM 125 I-labeled RANTES or MIP-1 α with or without unlabeled competitor (RANTES or MIP-1 α) or various concentrations of compounds. The binding reactions were performed in 60 to 100 μ l of a binding buffer consisting of 10 mM HEPES pH 7.2, 1 mM CaCl_2 , 5 mM MgCl_2 , and 0.5% BSA (bovine serum albumin), for 60 min at room temperature. The binding reactions were terminated by harvesting the membranes by rapid filtration through glass fiber filters (GF/B or GF/C, Packard) which were presoaked in 0.3% polyethyleneimine. The filters were rinsed with approximately 600 μ l of binding buffer containing 0.5 M NaCl, dried, and the amount of bound radioactivity was determined by scintillation counting in a Topcount beta-plate counter.

The activities of test compounds are reported in the Table below as IC_{50} values or the inhibitor concentration required for 50% inhibition of specific binding in receptor binding assays using 125 I-RANTES or 125 MIP-1 α as ligand and THP-1 cell membranes. Specific binding is defined as the total binding minus the non-specific binding; non-specific binding is the amount of cpm still detected in the presence of excess unlabeled Rantes or 125 MIP-1 α .

Table

BIOLOGICAL DATA


	Example	IC ₅₀ (μM)
5	1	0.088
	2	0.052
	3	0.11
	4	0.39
	5	0.19
10	6	0.30
	7	0.38
	10	0.097
	11	11
	12	0.099
15	13	0.38
	14	0.28
	15	0.61
	16	0.079
	17	0.070
20	18	0.055
	19	0.059
	22	0.69
	23	2.2
	24	0.16
25	25	0.13
	26	0.61
	27	0.48

Those skilled in the art will be able to recognize, or be able to ascertain, using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such
5 equivalents are intended to be encompassed by the following claims.

CLAIMS

What is claimed:

1. A method of treating a disease associated with aberrant leukocyte recruitment and/or activation comprising administering to a subject in need thereof a therapeutically effective amount of a compound represented by the following structural formula:



and physiologically acceptable salts thereof,

wherein:

Y is a covalent bond, -O- or -CO-;


n is an integer from one to about five;

X is a covalent bond or -CO-;

M is $>\text{NR}_2$ or $>\text{CR}_1\text{R}_2$;

R₁ is -H, -OH, an aliphatic group, -O-(aliphatic group), -SH or -S-(aliphatic group);

R₂ is an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzylic group, a substituted benzylic group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group;




Z is represented by the following structural formula:

5 wherein Ring C is a substituted or unsubstituted C_6 to C_8 non-aromatic carbocyclic ring or a substituted or unsubstituted non-aromatic heterocyclic ring and is bonded to the remainder of the molecule by a single covalent bond between Y and a carbon atom in Ring C; and

10 Ring A and Ring B are each, independently, substituted or unsubstituted.

2. The method of Claim 1 wherein X is a covalent bond and Y is a single covalent bond between a carbon atom in Ring C and the $(CH_2)_n$ moiety.

15 3. The method of Claim 2 wherein Z is represented by a structural formula selected from:




wherein:

X₁ is -S-, -CH₂- or -CH₂S-; and

W is -H or an electron withdrawing group.

- 5 4. The method of Claim 3 wherein Z is represented by the following structural formula:




5. The method of Claim 4 wherein W is -H or -CN.
6. The method of Claim 5 wherein R₁ is -OH.
- 10 7. The method of Claim 6 wherein M is >C(OH)R₂ and n is three.
8. The method of Claim 7 wherein R₂ is a substituted or unsubstituted aromatic group.

9. The method of Claim 1 wherein X is a covalent bond and Y is -CO-.

10. The method of Claim 2 wherein:

Z is represented by a structural formula selected from:



wherein:

X_1 is -S-, -CH₂- or -CH₂S-;

10 W is -H, -CN, alkylsulfonyl, carboxamido or carboxyalkyl;

Ring A is substituted with R₈ and R₉;


R₈ and R₉ are each, independently, -H, a halogen, alkoxy or alkyl, or

15 R₈ and R₉, taken together with Ring A, form a naphthyl group;


n is an integer from 2-5;

M is >N(alkanoyl), >N(aroyl), >N(aralkoyl), >N(alkyl), >N(aralkyl), >N(cycloalkyl), >C(OH)(aryl) or
20 >CH(heteroaryl).


11. The method of Claim 1 wherein the compound is represented by a structural formula selected from:



or




12. The method of Claim 2 wherein Z is represented by a structural formula selected from:




wherein Rings A, B and C are each, independently, substituted or unsubstituted.

13. A compound represented by the following structural
5 formula:



and physiologically acceptable salts thereof,
wherein:

- 10 Z is represented by the following structural
formula:



wherein Ring C is a C_6 to C_8 non-aromatic carbocyclic ring or a non-aromatic heterocyclic ring,

each ring in Z is independently substituted or unsubstituted; and

Z is connected to the remainder of the molecule by a single covalent bond between a carbon atom in Ring C and the $(CH_2)_n$ moiety.


n is an integer from one to about five;

M is $>NR_2$ or $>CR_1R_2$;

R_1 is -H, -OH, an aliphatic group, -O-(aliphatic group), -SH or -S-(aliphatic group);

R_2 is an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzylic group, a substituted benzylic group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group.

14. A compound represented by the following structural formula:



and physiologically acceptable salts thereof, wherein:

M is $>NR_2$ or $>CR_1R_2$;

R_1 is -H, -OH, an aliphatic group, -O-(aliphatic group), -SH or -S-(aliphatic group);


R_2 is an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzylic group, a substituted benzylic group, a non-

aromatic heterocyclic group or a substituted non-aromatic heterocyclic group;

n is an integer from one to about five;

Z is represented by the following structural formula:

5



W is an electron withdrawing group; and
at least one of Ring A or Ring B is substituted.

10 15. The compound of Claim 14 wherein W is -CN.

16. The compound of Claim 15 wherein R₁ is -OH.

17. The compound of Claim 16 wherein M is >C(OH)R₂ and n is three.

18. The compound of Claim 17 wherein R₂ is a substituted or
15 unsubstituted aromatic group.

19. The compound of Claim 14 wherein:

W is -H, -CN, alkylsulfonyl, carboxamido or
carboxyalkyl;

n is an integer from 2-5;


20

Ring A is substituted with R₈ and R₉, wherein

R_8 and R_9 are each, independently, a halogen, alkoxy or alkyl, or R_8 and R_9 , taken together with Ring A, form a naphthyl group; and

M is $>N(\text{alkanoyl})$, $>N(\text{aroyl})$, $>N(\text{aralkoyl})$,
 5 $>N(\text{alkyl})$, $>N(\text{aralkyl})$, $>N(\text{cycloalkyl})$, $>C(OH)(\text{aryl})$ or
 $>CH(\text{heteroaryl})$.

20. Use of a compound for the manufacture of a medicament for the treatment or prevention of a disease in a subject, said disease being associated with aberrant
 10 leukocyte recruitment and/or activation, and said compound being represented by the following structural formula:




and physiologically acceptable salts thereof,
 15 wherein:

Y is a covalent bond, -O- or -CO-;
 n is an integer from one to about five;
 X is a covalent bond or -CO-;
 M is $>NR_2$ or $>CR_1R_2$;
 20 R_1 is -H, -OH, an aliphatic group, -O-(aliphatic group), -SH or -S-(aliphatic group);
 R_2 is an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzylic group, a substituted benzylic group, a non-

aromatic heterocyclic group or a substituted non-aromatic heterocyclic group;

Z is represented by the following structural formula:




5 wherein Ring C is a substituted or unsubstituted
C₆ to C₈ non-aromatic carbocyclic ring or a substituted
or unsubstituted non-aromatic heterocyclic ring and is
bonded to the remainder of the molecule by a single
covalent bond between Y and a carbon atom in Ring C;
10 and

Ring A and Ring B are each, independently,
substituted or unsubstituted.

21. The use of Claim 20 wherein X is a covalent bond and Y
is a single covalent bond between a carbon atom in Ring
15 C and the (CH₂)_n moiety.

22. The use of Claim 21 wherein Z is represented by a
structural formula selected from:



wherein:


X_1 is -S-, -CH₂- or -CH₂S-; and

W is -H or an electron withdrawing group.

5

23. The use of Claim 20 wherein:

Z is represented by a structural formula selected from:



10

wherein:

X_1 is -S-, -CH₂- or -CH₂S-;

W is -H, -CN, alkylsulfonyl, carboxamido or carboxyalkyl;

15

Ring A is substituted with R₈ and R₉;


R₈ and R₉ are each, independently, -H, a halogen, alkoxy or alkyl, or

R_8 and R_9 , taken together with Ring A, form a naphthyl group;


n is an integer from 2-5;

5 M is $>N(\text{alkanoyl})$, $>N(\text{aroyl})$, $>N(\text{aralkoyl})$,
 $>N(\text{alkyl})$, $>N(\text{aralkyl})$, $>N(\text{cycloalkyl})$, $>C(\text{OH})(\text{aryl})$ or
 $>CH(\text{heteroaryl})$.

24. The use of Claim 20 wherein the compound is represented by a structural formula selected from:




25. The use of Claim 20 wherein Z is represented by a structural formula selected from:



wherein Rings A, B and C are each, independently,
5 substituted or unsubstituted.

26. Use of a compound for the manufacture of a medicament
for the treatment or prevention of a disease associated
with aberrant leukocyte recruitment and/or activation
in a subject, said disease being selected from
10 arthritis, psoriasis, multiple sclerosis, ulcerative
colitis, Crohn's disease, allergy, asthma, AIDS
associated encephalitis, AIDS related maculopapular
skin eruption, AIDS related interstitial pneumonia,
AIDS related enteropathy, AIDS related periportal
15 hepatic inflammation and AIDS related glomerulo
nephritis, and said compound being represented by the
following structural formula:



and physiologically acceptable salts thereof,
wherein:

Y is a covalent bond, -O- or -CO-;

n is an integer from one to about five;


5 X is a covalent bond or -CO-;

M is $>NR_2$ or $>CR_1R_2$;

R₁ is -H, -OH, an aliphatic group, -O-(aliphatic group), -SH or -S-(aliphatic group);

10 R₂ is an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzylic group, a substituted benzylic group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group;

15 Z is represented by the following structural formula:




20 wherein Ring C is a substituted or unsubstituted C₆ to C₈ non-aromatic carbocyclic ring or a substituted or unsubstituted non-aromatic heterocyclic ring and is bonded to the remainder of the molecule by a single covalent bond between Y and a carbon atom in Ring C;
and

Ring A and Ring B are each, independently, substituted or unsubstituted.

27. The use of Claim 26 wherein X is a covalent bond and Y is a single covalent bond between a carbon atom in Ring C and the $(CH_2)_n$ moiety.

28. The use of Claim 27 wherein Z is represented by a structural formula selected from:



wherein:


X_1 is -S-, -CH₂- or -CH₂S-; and

W is -H or an electron withdrawing group.

10

29. The use of Claim 27 wherein:

Z is represented by a structural formula selected from:



15

wherein:

X₁ is -S-, -CH₂- or -CH₂S-;

W is -H, -CN, alkylsulfonyl, carboxamido or carboxyalkyl;

5 Ring A is substituted with R₈ and R₉;



R₈ and R₉ are each, independently, -H, a halogen, alkoxy or alkyl, or

R₈ and R₉, taken together with Ring A, form a naphthyl group;


10 n is an integer from 2-5;

M is >N(alkanoyl), >N(aroyle), >N(aralkoyl), >N(alkyl), >N(aralkyl), >N(cycloalkyl), >C(OH)(aryl) or >CH(heteroaryl).

30. The use of Claim 26 wherein the compound is represented
15 by a structural formula selected from:



31. The use of Claim 26 wherein Z is represented by a structural formula selected from:



wherein Rings A, B and C are each, independently,
substituted or unsubstituted.

1/9




Figure 1

2/9




Figure 2

SUBSTITUTE SHEET (RULE 26)

3/9




Figure 3

SUBSTITUTE SHEET (RULE 26)

4/9















Figure 4A

SUBSTITUTE SHEET (RULE 26)

5/9















Figure 4B
SUBSTITUTE SHEET (RULE 26)















Figure 4C

7/9












Figure 4D

8/9




Figure 4E

9/9








Figure 4F

SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/01265

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D211/52 A61K31/445 C07D405/06 C07D409/06 C07D493/04
 //(C07D493/04, 317:00, 313:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEMICAL ABSTRACTS, vol. 109, no. 11, 1988 Columbus, Ohio, US; abstract no. 92794g, M. PROTIVA ETAL.: "Substituted 11-(piperidinoalkyl)-6,11-dihydrodibenzo'b ,e]thiepi-11-carbonitriles useful as antidiarrheal drugs" page 689; XP002104474 see abstract & CS 240 698 A (PROTIVA) 1 June 1987	13
X	GB 1 109 847 A (RHONE-POULENC) 18 April 1968 see examples 7,10,14 --- -/-	13

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

7 June 1999

Date of mailing of the international search report

18/06/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
 Fax: (+31-70) 340-3016

Authorized officer

Alfaro Faus, I

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/01265

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB 1 213 172 A (FUJISAWA) 18 November 1970 see examples 2-1,2-2 ---	13
P,X	WO 98 02151 A (LEUKOSITE) 22 January 1998 see claim 1; tables 3,4 ---	1,13
A	WO 97 44329 A (TEIJN) 27 November 1997 see claims 1,9 -----	1

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/01265

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-12 and 20-22
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 1 to 12 and 20 to 22 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

In view of the extremely broad Markush claims, the search was executed with due regard to the PCT Search Guidelines (PCT/GL/2), C-III, paragraph 2.1, 2.3 read in conjunction with 3.7 and Rule 33.3 PCT, i.e. particular emphasis was put on the inventive concept, as illustrated by the examples of the description and covered the entire subject-matter to which the claims are directed.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. Jonal Application No

PCT/US 99/01265

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB 1109847 A		BE 664609 A	
		CH 436269 A	
		CH 448071 A	
		DE 1620156 A	02-01-1970
		DK 119253 B	07-12-1970
		DK 115988 B	01-12-1969
		FI 42324 B	31-03-1970
		FR 145 M	
		FR 4069 M	
		FR 89653 E	02-11-1967
		FR 89659 E	02-11-1967
		FR 1488211 A	06-11-1967
		LU 48732 A	02-08-1965
		NL 6506574 A	02-12-1965
		SE 312549 B	21-07-1969
		US 3480624 A	25-11-1969
GB 1213172 A	18-11-1970	CA 960664 A	07-01-1975
		CH 518301 A	31-01-1972
		CH 533129 A	31-01-1973
		DE 1770242 A	07-10-1971
		ES 353213 A	01-10-1969
		FR 7638 M	02-02-1970
		SE 366047 B	08-04-1974
		US 3625974 A	07-12-1971
WO 9802151 A	22-01-1998	AU 3659897 A	09-02-1998
WO 9744329 A	27-11-1997	JP 9309877 A	02-12-1997
		AU 3135497 A	09-12-1997
		EP 0914319 A	12-05-1999

